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ACTIVE IMMUNIZATION AGAINST HEPATITIS B VIRUS (HBV) WITH LOW-DOSES OF 
PLASMA-DERIVED VACCINE BY INTRADERMAL ROUTE 
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S U M M A R Y 
Schedule for vaccinat ion against H B V infection has usually been based on three 
separate injections of 20 meg of the vaccine by intramuscular route. One of the 
main shortcomings to its use in large scale programs has been its h igh cost. Ninety 
out of 300 health workers were submitted to three injections of 2 mcg of p lasma-
derived vaccine (PDV) by intradermal ( ID) route on days 0, 30, and 180. An t i -HBs 
was detected in 74 (82.2%) after the second dose and in 80 (88.9%) after the third 
dose, a non-significant difference. However, levels above 10 times the cut-off were 
observed in 29 (32.2%) and 77 (85.5%), respectively (p < 0.001). The results showed 
that a low-dose schedule is effective when used in health workers and should be 
tried with other r isk groups. 
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I N T R O D U C T I O N 
P lasma-der i ved vacc ine is very effective 
against H B V 1 3 4 8 ' 1 5 . The protective antibody 
against surface antigen (ant i -HBs) develops af-
ter three doses of the vaccine in more than 90% 
of the general popu la t ion 3 . T h e recomended 
schedule in most programs of active immuni-
zation has been three separate injections of 20 
meg per dose by intramuscular (IM) route in del-
toid region 3 4 7 1 5 . One of the main difficulties 
to apply this program in underdeveloped coun-
tries is its high cost. Fo r this reason different 
schedules with lower doses have been tried, such 
as 10, 5 and 2.5 meg by intramuscular routes 2 
7. i2 , i3 More recently, 2 meg by intradermal ( ID) 
route was employed, with promising results 5 8 
9, io , i3 However, the samples in most studies were 
rather smal l . 
The aim of this study was to investigate the 
efficacy of the plasma-derived vaccine by using 
2 meg by I D route. 
M A T E R I A L A N D M E T H O D S 
A total of 300 hospital health workers were 
submitted to a serological study of H B V mar 
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kers. Hepati t is B surface antigen (HBsAg) and 
its antibody (ant i -HBs) and total core antibody 
(ant i-HBc) were studied by using an enzyme-lin­
ked immunoassay ( A U S Z Y M E I I , A U S A B E I A 
and C O R Z Y M E , respectively, produced by A B ­
B O T T L A B O R A T O R I E S , U. S . A.) . The sche­
dule of active immunizat ion was similar to that 
used by M I L L E R et a l 1 1 : one dose at day zero, 
and subsequent doses at one and six-month in­
tervals using 2 meg by I D route. Only workers 
without H B V markers were submitted to vacci­
nation on a voluntary basis. 
Seroconversion to ant i -HBs was studied im­
mediately before and one month after the third 
dose. A rough semiquantitat ive determination 
was based on the value of the cut-off. I t was con­
sidered a good antibody response when the value 
obtained was above then times the cut-off level 8 . 
In the screening of the 300 workers, an t i -HBc 
was detected in 43 (14.3%), including 9 (3.0%) 
with H B s A g and 34 (11.3%) of ant i -HBs (Figure 
1). Only 90 (35.0%) out of 257 workers without 
H B V markers accepted the vaccinat ion schedu­
le. Th i s group consisted of 68 females and 22 
males; with a mean age of 37.4 ± 8.4 years (22 
- 56 years). 
R E S U L T S 
The results showed that, an t i -HBs was de 
tected in 74 (82.2%c) and 80 (88.9%) workers, res­
pectively before and after the third dose, a non­
signif icant difference (chi-square = 1.1238, 0.30 
> p > 0.20, F igure 2). However, a good antibody 
response was obtained in only 29 out of 90 (32.2% ) 
after the second dose and in 77 out of 90 (85.5%) 
workers after the th i rd dose (ch i -square = 
50.6909, p < 0.001), as shown in F igure 3. 
D I S C U S S I O N 
Our results clearly show that vaccinat ion 
with three doses of 2 meg of H B V plasma-derived 
by I D route produces a high number of serocon­
version to ant i -HBs (88.9%). These results agree 
with those publ ished by M I L L E R et a l 1 1 and 
R E D F I E L D et a l 1 4 . T o our knowledge only few 
papers based on such a schedule of immuniza­
tion have been published to date 5 9 1 0 1 1 1 4 1 6 . 
I t is worth mentioning that the seroconversion 
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rate observed in those studies varied from 74.0 
to 100.0%. Besides, a comparison between 20 
meg by IM route and 2 meg by I D route showed 
no signif icant difference in the seroconversion 
rate 5 H , though the levels of ant i -HBs tend to 
be lower after reduced doses 2 , 5 1 6 . 
In our material, a low percentage of subjects 
(35.0%) accepted to be vaccinated against H B V . 
The main reason for this h igh refuse was the 
unjustifiable fear that plasma-derived vaccine 
would be contaminated by human immunodefi-
ciency virus 6 . 
R E D F I E L D et a l 1 4 and M U L L E Y et a l 1 2 em-
phazised that vaccine cost remains a major obs-
tacle for the expansion of H B V vaccinat ion pro-
grams. 
The low doses schedule used in this study 
proved to be effective, and, if confirmed in field 
studies 1 7 , it should be considered in large-scale 
programs of immunizat ion against H B V . 
R E S U M O 
Imunização at iva contra o v í rus da Hepatite 
B com baixas doses da vacina plasma derivada 
por v ia intradérmica. 
O esquema habi tualmente ut i l izado para 
imunização at iva contra o vírus da hepatite B 
( V H B ) consiste em 3 doses de 20 mcg por v ia 
in t ramuscu lar (IM) no deltóide. Um dos proble-
mas quanto à sua uti l ização em larga escala refe-
re-se ao seu custo elevado. Poucas publicações 
têm se referido a doses menores, de 10 mcg IM 
ou 2 mcg intradérmica ( ID) . Pesquisou-se em 
300 funcionários da área da saúde o ant i -HBc 
total. Todos os marcadores foram determinados 
pela técnica de E L I S A . E m 43 (14,3%) o marca-
dor foi positivo, correspondendo a 9 (3,0%) com 
A g H B s e a 34 (11,3%) com ant i -HBs. Aos 257 fun-
cionários sem ant i -HBc propôs-se um esquema 
de vacinação, que foi aceito por 90 (35,0% ). Idade 
média de 37,4 ± 8,4 anos, l imites de 22 - 56 anos 
e 68 do sexo feminino. Esquema: 3 doses de 2 
meg por v ia I D com intervalos de 1 e 6 meses. 
O ant i -HBs, pesquisado após a 2ª dose mostrou 
se positivo em 74 (82,2%) e após a 3ª dose em 
80 (88,9%) — diferença não signif icat iva. Contu 
do, a quantif icação do ant i -HBs mostrou níveis 
10 vezes acima do "cut -of f em 29 (32,2%) e em 
77 (85,5%r) após a 2ª e 3ª doses, respectivamente 
(p < 0,001). Portanto, o esquema proposto mos-
trou-se válido para este tipo de população e, ape-
sar da freqüência semelhante de sero-conversão 
após a 2? e 3? doses, há necessidade desta úl t ima 
para aumentar o título de anticorpos. 
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